CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
CI-581a +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02596022
NCT02596022Phase 2Completed

The Effect of Glutamatergic Modulation on Cocaine Self-administration

New York State Psychiatric Institute·interventional·Posted Nov 4, 2015·Updated Jun 15, 2018

In Brief

A Phase 2 clinical trial evaluating CI-581a and CI-581b for Cocaine Dependence. Completed, enrolled 18 participants.

Detailed Summary

Repeated drug consumption may progress to problematic use by triggering neuroplastic adaptations that attenuate sensitivity to natural rewards while increasing reactivity to craving and drug cues. Converging evidence suggests that glutamate modulation may work to correct these adaptations and rapidly restore motivation for delayed non-drug rewards relative to immediate drug use. Using an established laboratory model aimed at evaluating behavioral shifts in the salience of cocaine now vs. money later, the investigators will test the effect of CI-581a on cocaine self-administration as compared to the active control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 4, 2015
Enrollment StartJun 1, 2013
Primary CompletionJun 1, 2015
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 10.7 years ago

Interventions

CI-581adrug

a 50 minute infusion 24 hours prior to cocaine self-administration session

CI-581bdrug

a 50 minute infusion 24 hours prior to cocaine self-administration session